About NEXGEL, Inc.
https://nexgel.comNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It provides facemasks, undereye patches, blister shield foot care, hexagel, cracked heel repair patches, and fever patch.
CEO
Adam R. Levy
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:550K
Value:$95.75K
WARBERG ASSET MANAGEMENT LLC
Shares:166.86K
Value:$29.05K
EMPERY ASSET MANAGEMENT, LP
Shares:90K
Value:$15.67K
Summary
Showing Top 3 of 7
About NEXGEL, Inc.
https://nexgel.comNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It provides facemasks, undereye patches, blister shield foot care, hexagel, cracked heel repair patches, and fever patch.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.93M ▲ | $1.97M ▲ | $-653K ▲ | -22.26% ▲ | $-0.08 ▲ | $-524K ▼ |
| Q2-2025 | $2.88M ▲ | $1.89M ▼ | $-665K ▲ | -23.06% ▲ | $-0.09 ▲ | $-520K ▲ |
| Q1-2025 | $2.81M ▼ | $1.97M ▲ | $-712K ▲ | -25.37% ▲ | $-0.09 ▲ | $-531K ▲ |
| Q4-2024 | $3.04M ▲ | $1.62M ▼ | $-850K ▼ | -27.95% ▼ | $-0.12 ▼ | $-660K ▼ |
| Q3-2024 | $2.94M | $2.07M | $-693K | -23.57% | $-0.11 | $-550K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $938K ▲ | $11.62M ▲ | $6.04M ▲ | $5.19M ▲ |
| Q2-2025 | $725K ▼ | $9.71M ▼ | $4.66M ▼ | $4.67M ▼ |
| Q1-2025 | $1.19M ▼ | $10.44M ▼ | $4.87M ▼ | $5.21M ▼ |
| Q4-2024 | $1.81M ▲ | $10.98M ▲ | $4.9M ▼ | $5.75M ▲ |
| Q3-2024 | $1.06M | $10.57M | $5.59M | $4.69M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-653K ▲ | $-785K ▼ | $-8K ▲ | $1.93M ▲ | $1.13M ▲ | $-793K ▼ |
| Q2-2025 | $-665K ▲ | $-407K ▼ | $-20K ▼ | $-40K ▲ | $-467K ▲ | $-427K ▼ |
| Q1-2025 | $-712K ▲ | $-400K ▲ | $0 ▲ | $-215K ▼ | $-615K ▼ | $-400K ▲ |
| Q4-2024 | $-850K ▼ | $-859K ▲ | $-63K ▼ | $1.67M ▲ | $748K ▲ | $-928K ▲ |
| Q3-2024 | $-693K | $-1.22M | $-8K | $1.21M | $-10K | $-1.23M |
Revenue by Products
| Product | Q2-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Contract Manufacturing | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Incomes | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Adam R. Levy
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:550K
Value:$95.75K
WARBERG ASSET MANAGEMENT LLC
Shares:166.86K
Value:$29.05K
EMPERY ASSET MANAGEMENT, LP
Shares:90K
Value:$15.67K
Summary
Showing Top 3 of 7